financetom
Business
financetom
/
Business
/
Harley-Davidson Could See Decline in Shipments, US Sales, EPS in 2025, UBS Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Harley-Davidson Could See Decline in Shipments, US Sales, EPS in 2025, UBS Says
Jan 24, 2025 9:21 AM

11:58 AM EST, 01/24/2025 (MT Newswires) -- Harley-Davidson ( HOG ) could reduce shipments by 5% year-over-year in 2025, which is worse than the market's expectation of flat shipments, UBS said in a note Thursday.

The analysts, including Robin M. Farley, said the company's goal to maintain flat inventory for Q4 and its higher-margin expectations for 2025 suggest that the company may have initially expected retail growth in 2025, similar to its projections for 2024. However, the analysts think this is unlikely because they don't expect major model changes like the new Touring design last year. Retail declines in Q4 might have reduced their initial optimism.

The analysts also said they believe the company's US retail sales in October to November may have dropped by nearly double digits, following last year's Q4 declines, and early December checks also showed very negative results. Aside from macroeconomic factors like interest rates, dealers pointed to stricter credit requirements from Harley-Davidson Financial Services. The first quarter of 2025 is likely starting off weak, the analysts said, as California is the largest US state for motorcycle sales, accounting for around 10% of total US sales, and more during off-peak months in January to February. This could negatively impact Q1 sales.

The analysts estimate the adjusted earnings per share for fiscal year 2025 to be $3.81, which is below the street consensus estimate of $3.97. They also estimate that a 1% change in shipments will result in a 2-cent change in EPS.

UBS has a neutral rating and price target of $35 on Harley-Davidson ( HOG ).

Price: 28.33, Change: -0.40, Percent Change: -1.39

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Atlassian Insider Sold Shares Worth $1,156,861, According to a Recent SEC Filing
Atlassian Insider Sold Shares Worth $1,156,861, According to a Recent SEC Filing
Oct 9, 2025
05:37 PM EDT, 10/09/2025 (MT Newswires) -- Scott Farquhar, 10% Owner, Director, on October 08, 2025, sold 7,665 shares in Atlassian ( TEAM ) for $1,156,861. Following the Form 4 filing with the SEC, Farquhar has control over a total of 444,570 Class A common shares of the company, with 444,570 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1650372/000166612125000042/xslF345X05/primarydocument.xml ...
CVS has over 81% of members in high-rated Medicare Advantage plans for 2026
CVS has over 81% of members in high-rated Medicare Advantage plans for 2026
Oct 9, 2025
Oct 9 (Reuters) - CVS Health ( CVS ) said on Thursday that its Aetna insurance business has over 81% of members in Medicare Advantage plans that are rated 4 stars or higher for 2026. ...
Coreweave Insider Sold Shares Worth $2,119,125, According to a Recent SEC Filing
Coreweave Insider Sold Shares Worth $2,119,125, According to a Recent SEC Filing
Oct 9, 2025
05:38 PM EDT, 10/09/2025 (MT Newswires) -- Michael N Intrator, 10% Owner, Director, CEO and President, on October 07, 2025, sold 15,174 shares in Coreweave ( CRWV ) for $2,119,125. SEC Filing: https://www.sec.gov/Archives/edgar/data/1769628/000205803725000017/xslF345X05/form4-10092025_091021.xml ...
Phibro Animal Health, Lighthouse Pharmaceuticals Collaborate on Canine Periodontal Treatment
Phibro Animal Health, Lighthouse Pharmaceuticals Collaborate on Canine Periodontal Treatment
Oct 9, 2025
05:34 PM EDT, 10/09/2025 (MT Newswires) -- Phibro Animal Health ( PAHC ) said late Thursday it has signed a licensing agreement with Lighthouse Pharmaceuticals to develop and commercialize a new therapeutic compound aimed at improving periodontal health in companion animals. Financial details weren't disclosed. The deal grants Phibro exclusive global rights to develop, manufacture, and market Lighthouse's proprietary canine...
Copyright 2023-2026 - www.financetom.com All Rights Reserved